



ADULT MEDICATION GUIDELINE					
Terbutaline					
Scope (Staff):	All WNHS Staff				
Scope (Area):	Obstetrics and Gynaecology				
This document should be read in conjunction with the Disclaimer .					

Quick Links

DoseAdministrationMonitoringPregnancy and Breastfeeding

Restrictions

Formulary: Unrestricted

Medication Class

Short acting Beta₂ agonist

Presentation

Injection: 500microg/mL

Inhalation (Turbuhaler): 500microg/dose

Storage

Injection: Store at room temperature, below 25°C. Protect from light.

Inhalation (Turbuhaler): Store at room temperature, below 30°C. Replace cap firmly after each

use.

Dose

Tocolysis

IV Injection:

250 microg (0.5 mL) as a single dose.

Subcutaneous Injection (if no IV access):

250 microg (0.5 mL) as a single dose.

External cephalic version (ECV):

Subcutaneous:

250 microg (0.5 mL) as a single dose, given 30 minutes prior to procedure.

<u>Uterine inversion / hyperstimulation / hypertonus / tachysystole</u>

Subcutaneous:

250 microg (0.5 mL) as a single dose.

Administration

Refer to the Australian Injectable Drugs Handbook.

Monitoring

Refer to relevant WNHS Clinical Practice Guidelines.

Pregnancy

1st Trimester: Considered safe to use
2nd Trimester: Considered safe to use
3rd Trimester: Considered safe to use

Breastfeeding

Safe to use

Related Policies, Procedures & Guidelines

WNHS Clinical Practice Guidelines:

Fetal compromise (acute): Management if suspected

Abnormalities of Lie / Presentation

Induction of Labour (intranet access only)

Cord Prolapse: Umbilical

Postpartum complications (intranet access only)

References

The Royal Women's Hospital. Terbutaline. In: Pregnancy and Breastfeeding Medicines Guide [Internet]. Parkville (Victoria): The Royal Women's Hospital; 2022 [cited 2022 May 12]. Available from: https://thewomenspbmg.org.au/

Society of Hospital Pharmacists of Australia. Terbutaline. In: Australian Injectable Drugs Handbook [Internet]. [St Leonards, New South Wales]: Health Communication Network; 2022 [cited 2022 May 12]. Available from: http://aidh.hcn.com.au

The Royal Women's Hospital. Terbutaline (acute) – Administration of terbutaline [Internet].

The health impact upon Aboriginal people has been considered, and where relevant incorporated and appropriately addressed in the development of this document (insert ISD Number). (Please refer to the Aboriginal Health Impact Statement and Declaration for Department of Health and Health Service Provider Guidelines – please delete once you have completed this).

Keywords	Terbutaline, Tocolysis, premature labour, Asthma, bricanyl, tocolytic, external cephalic version, ECV, cord prolapse							
Document Owner:	Chief Pharmacist							
Author/ Reviewer	KEMH Pharmacy Department							
Version Info:	2.0							
Date First Issued:	July 2015	Last Reviewed:	May 2022		Review Date:	May 2025		
Endorsed by:	Medicines and Therapeutics Committee				Date:	05/07/2022		
NSQHS Standards Applicable:	Std 1: Clinical Governance			Std 5: Comprehensive Care				
	Std 2: Partnering with Consumers				Std 6: Communicating for Safety			
	Std 3: Preventing and Controlling Healthcare Associated Infection				Std 7: Blood Management			
	Std 4: Medication Safety				Std 8: Recognising and Responding to Acute Deterioration			
Printed or personally saved electronic copies of this document are considered uncontrolled.								
Access the current version from WNHS HealthPoint.								

This document can be made available in alternative formats on request for a person with a disability.

© Women and Newborn Health Service 2022

Copyright of this material is vested in the State of Western Australia unless otherwise indicated. Apart from any fair dealing for the purposes of private study, research, criticism or review, as permitted under the provisions of the Copyright Act 1968, no part may be reproduced or re-used for any purposes whatsoever without written permission of the State of Western Australia.